{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:52:49Z","timestamp":1773093169583,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000297","name":"FRAXA Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000297","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fragile X syndrome (FXS), an X-chromosome linked intellectual disability, is the leading monogenetic cause of autism spectrum disorder (ASD), a neurodevelopmental condition that currently has no specific drug treatment. Building upon the demonstrated therapeutic effects on spatial memory of bryostatin-1, a relatively specific activator of protein kinase C (PKC)\u03b5, (also of PKC\u03b1) on impaired synaptic plasticity\/maturation and spatial learning and memory in FXS mice, we investigated whether bryostatin-1 might affect the autistic phenotypes and other behaviors, including open field activity, activities of daily living (nesting and marble burying), at the effective therapeutic dose for spatial memory deficits. Further evaluation included other non-spatial learning and memory tasks. Interestingly, a short period of treatment (5\u00a0weeks) only produced very limited or no therapeutic effects on the autistic and cognitive phenotypes in the <jats:italic>Fmr1<\/jats:italic> KO2 mice, while a longer treatment (13\u00a0weeks) with the same dose of bryostatin-1 effectively rescued the autistic and non-spatial learning deficit cognitive phenotypes. It is possible that longer-term treatment would result in further improvement in these fragile X phenotypes. This effect is clearly different from other treatment strategies tested to date, in that the drug shows little acute effect, but strong long-term effects. It also shows no evidence of tolerance, which has been a problem with other drug classes (mGluR5 antagonists, GABA-A and -B agonists). The results strongly suggest that, at appropriate dosing and therapeutic period, chronic bryostatin-1 may have great therapeutic value for both ASD and FXS.<\/jats:p>","DOI":"10.1038\/s41598-020-74848-6","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T10:03:14Z","timestamp":1603360994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4198-0821","authenticated-orcid":false,"given":"Patricia","family":"Cogram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Alkon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Crockford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M. J.","family":"Deacon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-8338","authenticated-orcid":false,"given":"Francisco","family":"Altimiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao-Kun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Tranfaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"74848_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/nn1765","volume":"9","author":"MK Belmonte","year":"2006","unstructured":"Belmonte, M. K. & Bourgeron, T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat. Neurosci. 9, 1221\u20131225 (2006).","journal-title":"Nat. Neurosci."},{"key":"74848_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1159\/000330213","volume":"33","author":"DB Budimirovic","year":"2011","unstructured":"Budimirovic, D. B. & Kaufmann, W. E. What can we learn about autism from studying fragile X syndrome?. Dev. Neurosci. 33, 379\u2013394 (2011).","journal-title":"Dev. Neurosci."},{"key":"74848_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41593-018-0287-x","volume":"22","author":"SS Tran","year":"2019","unstructured":"Tran, S. S. et al. Widespread RNA editing dysregulation in brains from autistic individuals. Nat. Neurosci. 22, 25\u201336 (2019).","journal-title":"Nat. Neurosci."},{"issue":"Pt A","key":"74848_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.brainres.2018.04.008","volume":"1693","author":"A Banerjee","year":"2018","unstructured":"Banerjee, A. et al. Aberrant RNA translation in fragile X syndrome: From FMRP mechanisms to emerging therapeutic strategies. Brain Res. 1693(Pt A), 24\u201336 (2018).","journal-title":"Brain Res."},{"key":"74848_CR5","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.neuron.2019.02.041","volume":"101","author":"C Bagni","year":"2019","unstructured":"Bagni, C. & Zukin, R. S. A synaptic perspective of fragile X syndrome and autism spectrum disorders. Neuron 101, 1070\u20131088 (2019).","journal-title":"Neuron"},{"key":"74848_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1474-4422(06)70676-7","volume":"6","author":"S Jacquemont","year":"2007","unstructured":"Jacquemont, S., Hagerman, R. J., Hagerman, P. J. & Leehey, M. A. Fragile-X syndrome and fragile X-associated tremor\/ataxia syndrome: two faces of FMR1. Lancet Neurol. 6, 45\u201355 (2007).","journal-title":"Lancet Neurol."},{"key":"74848_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3389\/fpsyt.2018.00564","volume":"9","author":"RJ Hagerman","year":"2018","unstructured":"Hagerman, R. J. et al. Fragile X-associated neuropsychiatric disorders (FXAND). Front. Psychiatry 9, 564. https:\/\/doi.org\/10.3389\/fpsyt.2018.00564 (2018).","journal-title":"Front. Psychiatry"},{"key":"74848_CR8","first-page":"124","volume":"14","author":"A Mullard","year":"2015","unstructured":"Mullard, A. Fragile X disappointments upset autism ambitions. Nat. Rev. Drug Discov. 14, 124\u2013151 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"74848_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1126\/scitranslmed.aab4109","volume":"8","author":"E Berry-Kravis","year":"2016","unstructured":"Berry-Kravis, E. et al. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci. Transl. Med. 8, 321\u2013325 (2016).","journal-title":"Sci. Transl. Med."},{"key":"74848_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fnmol.2018.00041","volume":"11","author":"R Dahlhaus","year":"2018","unstructured":"Dahlhaus, R. Of men and mice: modeling the fragile X syndrome. Front. Mol. Neurosci. 11, 41. https:\/\/doi.org\/10.3389\/fnmol.2018.00041 (2018).","journal-title":"Front. Mol. Neurosci."},{"issue":"452","key":"74848_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3389\/fnmol.2017.00452","volume":"10","author":"RM Sar\u00e9","year":"2018","unstructured":"Sar\u00e9, R. M. et al. Negative effects of chronic rapamycin treatment on behavior in a mouse model of fragile X syndrome. Front. Mol. Neurosci. 10(452), 2017. https:\/\/doi.org\/10.3389\/fnmol.2017.00452 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"74848_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41593-018-0156-7","volume":"21","author":"PJ Zhu","year":"2018","unstructured":"Zhu, P. J., Chen, C. J., Mays, J., Stoica, L. & Costa-Mattioli, M. mTORC2, but not mTORC1, is required for hippocampal mGluR-LTD and associated behaviors. Nat. Neurosci. 21, 799\u2013802 (2018).","journal-title":"Nat. Neurosci."},{"key":"74848_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.tips.2006.12.002","volume":"28","author":"DL Alkon","year":"2007","unstructured":"Alkon, D. L., Sun, M.-K. & Nelson, T. J. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer\u2019s disease. Trends Pharmacol. Sci. 28, 51\u201360 (2007).","journal-title":"Trends Pharmacol. Sci."},{"key":"74848_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3233\/JAD-170161","volume":"58","author":"TJ Nelson","year":"2017","unstructured":"Nelson, T. J. et al. Bryostatin effects on cognitive function and PKC\u03b5 in Alzheimer\u2019s phase IIa and expanded access trials. J. Alzheimer\u2019s Dis. 58, 521\u2013535 (2017).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"74848_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3233\/JAD-180759","volume":"67","author":"MR Farlow","year":"2019","unstructured":"Farlow, M. R. et al. A randomized, double-blind, placebo-controlled, phase II study assessing safety, tolerability, and efficacy of bryostatin in the treatment of moderately seere to severe Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 67, 555\u2013570 (2019).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"74848_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1523\/JNEUROSCI.5209-10.2011","volume":"31","author":"J Hongpaisan","year":"2011","unstructured":"Hongpaisan, J., Sun, M.-K. & Alkon, D. L. PKC\u03b5 activation prevents synaptic loss, A\u03b2 elevation, and cognitive deficits in Alzheimer\u2019s disease transgenic mice. J. Neurosci. 31, 630\u2013643 (2011).","journal-title":"J. Neurosci."},{"key":"74848_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1124\/jpet.114.214098","volume":"349","author":"M-K Sun","year":"2014","unstructured":"Sun, M.-K., Hongpaisan, J., Lim, C. S. & Alkon, D. L. Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult fragile X mice. J. Pharmacol. Exp. Ther. 349, 393\u2013401 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"74848_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1124\/jpet.115.231100","volume":"357","author":"MK Sun","year":"2016","unstructured":"Sun, M. K., Hongpaisan, J. & Alkon, D. L. Rescue of synaptic phenotypes and spatial memory in young fragile X mice. J. Pharmacol. Exp. Ther. 357, 300\u2013310 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"74848_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neuroscience.2012.03.049","volume":"251","author":"CX He","year":"2013","unstructured":"He, C. X. & Portera-Cailliau, C. The trouble with spines in fragile X syndrome: density, maturity and plasticity. Neuroscience 251, 120\u2013128 (2013).","journal-title":"Neuroscience"},{"key":"74848_CR20","doi-asserted-by":"publisher","first-page":"19715","DOI":"10.1523\/JNEUROSCI.2514-13.2013","volume":"33","author":"R Padmashri","year":"2013","unstructured":"Padmashri, R., Reiner, B. C., Suresh, A., Spartz, E. & Dunaevsky, A. Altered structural and functional synaptic plasticity with motor skill learning in a mouse model of fragile X syndrome. J. Neurosci. 33, 19715\u201319723 (2013).","journal-title":"J. Neurosci."},{"key":"74848_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1523\/JNEUROSCI.1734-18.2018","volume":"39","author":"ED Arroyo","year":"2019","unstructured":"Arroyo, E. D., Fiole, D., Mantri, S., Huang, C. X. & Portera-Cailliau, C. Dendritic spines in early postnatal Fragile X mice are insensitive to novel sensory experience. J. Neurosci. 39, 412\u2013419 (2019).","journal-title":"J. Neurosci."},{"key":"74848_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.nbd.2005.08.019","volume":"21","author":"EJ Mientjes","year":"2006","unstructured":"Mientjes, E. J. et al. The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol. Dis. 21, 549\u2013555 (2006).","journal-title":"Neurobiol. Dis."},{"key":"74848_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bbr.2004.05.027","volume":"156","author":"RM Deacon","year":"2005","unstructured":"Deacon, R. M. & Rawlins, J. N. Hippocampal lesions, species-typical behaviours and anxiety in mice. Behav. Brain Res. 156, 241\u2013249 (2005).","journal-title":"Behav. Brain Res."},{"key":"74848_CR24","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nprot.2006.120","volume":"1","author":"RM Deacon","year":"2006","unstructured":"Deacon, R. M. Housing, husbandry and handling of rodents for behavioral experiments. Nat. Protoc. 1, 936\u2013946 (2006).","journal-title":"Nat. Protoc."},{"key":"74848_CR25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nprot.2006.170","volume":"1","author":"RM Deacon","year":"2006","unstructured":"Deacon, R. M. Assessing nest building in mice. Nat. Protoc. 1, 1117\u20131119 (2006).","journal-title":"Nat. Protoc."},{"key":"74848_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nprot.2006.20","volume":"1","author":"RM Deacon","year":"2006","unstructured":"Deacon, R. M. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat. Protoc. 1, 122\u2013124 (2006).","journal-title":"Nat. Protoc."},{"key":"74848_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/FBP.0b013e3283618afe","volume":"24","author":"M-K Sun","year":"2013","unstructured":"Sun, M.-K. & Alkon, D. L. Cerebral ischemia-induced difference in sensitivity to depression and potential therapeutics in rats. Behav. Pharmacol. 24, 222\u2013228 (2013).","journal-title":"Behav. Pharmacol"},{"key":"74848_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10802-018-0402-1","volume":"47","author":"CC Hudson","year":"2019","unstructured":"Hudson, C. C., Hall, L. & Harkness, K. L. Prevalence of depressive disorders in individuals with autism spectrum disorder: a meta-analysis. J. Abnorm. Child Psychol. 47, 165\u2013175 (2019).","journal-title":"J. Abnorm. Child Psychol."},{"key":"74848_CR29","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/mp.2017.221","volume":"23","author":"W Wang","year":"2018","unstructured":"Wang, W. et al. Treating a novel plasticity defect rescues episodic memory in Fragile X model mice. Mol. Psychiatry 23, 1798\u20131806 (2018).","journal-title":"Mol. Psychiatry"},{"key":"74848_CR30","doi-asserted-by":"publisher","first-page":"14653","DOI":"10.1038\/s41598-017-15028-x","volume":"7","author":"ME Gurney","year":"2017","unstructured":"Gurney, M. E., Cogram, P., Deacon, R. M., Rex, C. & Tranfaglia, M. Multiple behavior phenotypes of the fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D). Sci. Rep. 7, 14653 (2017).","journal-title":"Sci. Rep."},{"key":"74848_CR31","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/npp.2014.167","volume":"39","author":"S Gholizadeh","year":"2014","unstructured":"Gholizadeh, S., Arsenault, J., Xuan, I. C., Pacey, L. K. & Hampson, D. R. Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice. Neuropsychopharmacology 39, 3100\u20133111 (2014).","journal-title":"Neuropsychopharmacology"},{"key":"74848_CR32","doi-asserted-by":"publisher","first-page":"11298","DOI":"10.1523\/JNEUROSCI.2893-16.2017","volume":"37","author":"T Nomura","year":"2017","unstructured":"Nomura, T. et al. Delayed maturation of fast-spiking interneurons is rectified by activation of the TrkB receptor in the mouse model of fragile x syndrome. J. Neurosci. 37, 11298\u201311310 (2017).","journal-title":"J. Neurosci."},{"key":"74848_CR33","doi-asserted-by":"publisher","first-page":"8889","DOI":"10.1038\/s41598-018-26853-z","volume":"8","author":"T Arbab","year":"2018","unstructured":"Arbab, T., Pennartz, C. M. A. & Battaglia, F. P. Impaired hippocampal representation of place in the Fmr1-knockout mouse model of fragile X syndrome. Sci. Rep. 8, 8889 (2018).","journal-title":"Sci. Rep."},{"key":"74848_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.25100\/cm.v45i4.1810","volume":"45","author":"W Saldarriaga","year":"2014","unstructured":"Saldarriaga, W. et al. Fragile X syndrome. Colomb Med. (Cali) 45, 190\u2013198 (2014).","journal-title":"Colomb Med. (Cali)"},{"key":"74848_CR35","doi-asserted-by":"publisher","first-page":"27586","DOI":"10.1074\/jbc.M303740200","volume":"278","author":"N Detich","year":"2003","unstructured":"Detich, N., Bovenzi, V. & Szyf, M. Valproate induces replication-independent active DNA demethylation. J. Biol. Chem. 278, 27586\u201327592 (2003).","journal-title":"J. Biol. Chem."},{"key":"74848_CR36","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1172\/JCI63141","volume":"122","author":"C Bagni","year":"2012","unstructured":"Bagni, C., Tassone, F., Neri, G. & Hagerman, R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J. Clin. Invest. 122, 4314\u20134322 (2012).","journal-title":"J. Clin. Invest."},{"key":"74848_CR37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2018.01.012","volume":"172","author":"XS Liu","year":"2018","unstructured":"Liu, X. S. et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell 172, 979\u2013992 (2018).","journal-title":"Cell"},{"key":"74848_CR38","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.celrep.2019.02.026","volume":"26","author":"D Vershkov","year":"2019","unstructured":"Vershkov, D. et al. FMR1 reactivating treatments in fragile X iPSC-derived neural progenitors in vitro and in vivo. Cell Rep. 26, 2531\u20132539 (2019).","journal-title":"Cell Rep."},{"key":"74848_CR39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1542\/peds.2008-0317","volume":"123","author":"RJ Hagerman","year":"2009","unstructured":"Hagerman, R. J. et al. Advances in the treatment of fragile X syndrome. Pediatrics 123, 378\u2013390 (2009).","journal-title":"Pediatrics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74848-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:44:16Z","timestamp":1670363056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74848-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74848"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74848-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"3 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. Research support (including salaries, equipment, supplies, and other expenses) was provided by FRAXA Research Foundation, a no-for profit organization, that do not gain or lose financially through this publication. Drs. Robert Deacon, Michael Hurley, Francisco Altimiras and Patricia Cogram were supported under a FRAXA grant. Dr. Michael Tranfaglia is the medical director of FRAXA Research Foundation and has no conflict of interest in supporting this work. The experiments using Bryostatin1 for FXS were conducted when the authors, Drs. Alkon and Sun were full-time employees of the Blanchette Rockefeller Neurosciences Institute, USA. Dr. David Crockford, from Neurotrope Bioscience Inc., USA, provided Bryostatin 1 for the experimental work for this publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18058"}}